Clareo Health | Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy
Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histopathologically confirmed breast cancer (aged 18-80 years, inclusive).
Scheduled to receive or currently receiving intravenous chemotherapy, with at least 2 planned cycles.
Planned use of guideline-recommended triple antiemetic therapy (5-HT3 receptor antagonist + NK-1 receptor antagonist + dexamethasone).
ECOG performance status ≤ 2 and life expectancy ≥ 3 months.
Chemotherapy regimen classified as highly emetogenic risk according to CSCO, NCCN, or MASCC/ESMO antiemetic guidelines.
Able to understand the study procedures, voluntarily participate, and provide written informed consent.
You may not be if
History of allergy to essential oils.
History of vestibular dysfunction or intestinal obstruction.
Major cardiovascular or cerebrovascular event within the past 12 months (e.g., unstable angina, myocardial infarction, cerebral hemorrhage, cerebral infarction; asymptomatic lacunar infarction not requiring treatment is allowed).
Pregnancy, lactation, or possibility of pregnancy without willingness to use contraception.
History or current diagnosis of significant neurological or psychiatric disorders, including epilepsy or dementia.
Poor compliance anticipated, or any other condition that the investigator considers inappropriate for participation.
